Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Baradaran, Behzad  [Clear All Filters]
Journal Article
Sayadmanesh A, Azadbakht M, Yari K, Abedelahi A, Shafaei H, Shanehbandi D, Baradaran B, Basiri M. Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells. Cell J. 2023;25(10):674-687.
Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, et al. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother. 2021;137:111364.
Khiabani NAllahyarza, Doustvandi MAmin, Mohammadnejad F, Kohal ESalmani Ha, Boushehri N, Jafarlou M, Baradaran B. Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells. Exp Cell Res. 2023:113667.
Gharibi T, Barpour N, Hosseini A, Mohammadzadeh A, Marofi F, Ebrahimi-Kalan A, Nejati-Koshki K, Abdollahpour-Alitappeh M, Safaei S, Baghbani E, et al. Corrigendum to "STA-21, a small molecule STAT3 inhibitor, ameliorates experimental autoimmune encephalomyelitis by altering Th-17/Treg balance" [Int. Immunopharmacol. 119 (2023) 110160]. Int Immunopharmacol. 2023:110303.
Khanmiri JMotallebza, Alizadeh M, Esmaeili S, Gholami Z, Safarzadeh A, Khani-Eshratabadi M, Baghbanzadeh A, Alizadeh N, Baradaran B. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review. Cytotherapy. 2024.
Barpour N, Ghorbani M, Baradaran B, Jodari-Mohammadpour Z, Nejati-Koshki K, Abdollahpour-Alitappeh M, Dabbaghi R, Gharibi T. Development of an injectable chitosan-based hydrogel containing nano-hydroxy-apatite and alendronate for MSC-based therapy. Int J Biol Macromol. 2024:129737.
Mostafaei F, Hemmati S, Valizadeh H, Mahmoudian M, Sarfraz M, Abdi M, Torabi S, Baradaran B, Vosough M, Zakeri-Milani P. Enhanced intracellular accumulation and cytotoxicity of bortezomib against liver cancer cells using N-stearyl lactobionamide surface modified solid lipid nanoparticles. Int J Pharm. 2023:123635.
Heidari B, Gifani M, Shirazi A, Zarnani A-H, Baradaran B, Naderi MMehdi, Behzadi B, Borjian-Boroujeni S, Sarvari A, Lakpour N, et al. Enrichment of undifferentiated type a spermatogonia from goat testis using discontinuous percoll density gradient and differential plating. Avicenna J Med Biotechnol. 2014;6(2):94-103.
Maleki LAghebati, Majidi J, Baradaran B, Movassaghpour A, Abdolalizadeh J. Generation and Characterization of Anti-CD34 Monoclonal Antibodies that React with Hematopoietic Stem Cells. Cell J. 2014;16(3):361-6.
Lotfinegad P, Shamsasenjan K, Movassaghpour A, Majidi J, Baradaran B. Immunomodulatory Nature and Site Specific Affinity of Mesenchymal Stem Cells: a Hope in Cell Therapy. Adv Pharm Bull. 2014;4(1):5-13.
Maleki LAghebati, Majidi J, Baradaran B, Abdolalizadeh J, Kazemi T, Maleki AAghebati, Sepehr KSineh. Large Scale Generation and Characterization of Anti-Human CD34 Monoclonal Antibody in Ascetic Fluid of Balb/c Mice. Adv Pharm Bull. 2013;3(1):211-216.
Sepehr KSineh, Baradaran B, Majidi J, Abdolalizadeh J, Aghebati L, Shahneh FZare. Mass-Production and Characterization of Anti-CD20 Monoclonal Antibody in Peritoneum of Balb/c Mice. Adv Pharm Bull. 2013;3(1):109-113.
Asghariazar V, Kadkhodayi M, Sarailoo M, Jolfayi AGhaffari, Baradaran B. MicroRNA-143 as a potential tumor suppressor in cancer: An insight into molecular targets and signaling pathways. Pathol Res Pract. 2023;250:154792.
Mansoori B, Kiani S, Mezajin AAshrafi, Zandi P, Banaie H, Rostamzadeh D, Cho WC, Duijf PHG, Mansoori B, Baradaran B. MicroRNA-143-5p Suppresses ER-Positive Breast Cancer Development by Targeting Oncogenic HMGA2. Clin Breast Cancer. 2023.
Oroojalian F, Haghbin A, Baradaran B, Hemat N, Shahbazi M-A, Baghi HBannazadeh, Mokhtarzadeh A, Hamblin MR. Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. Int J Biol Macromol. 2020.
Yaghobi Z, Movassaghpour A, Talebi M, Shadbad MAbdoli, Hajiasgharzadeh K, Pourvahdani S, Baradaran B. The role of CD44 in cancer chemoresistance: a concise review. Eur J Pharmacol. 2021:174147.
Payandeh Z, Tazehkand APirpour, Barati G, Pouremamali F, Kahroba H, Baradaran B, Samadi N. Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance. Biochimie. 2020.
Alemohammad H, Asadzadeh Z, Azad RMotafakker, Hemmat N, Najafzadeh B, Vasefifar P, Najafi S, Baradaran B. Signaling pathways and microRNAs, the orchestrators of NANOG activity during cancer induction. Life Sci. 2020:118337.
Hajizadeh F, Ardebili SMoghadasza, Moornani MBaghi, Masjedi A, Atyabi F, Kiani M, Namdar A, Karpisheh V, Izadi S, Baradaran B, et al. Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. Eur J Pharmacol. 2020:173235.
Masjedi A, Ahmadi A, Atyabi F, Farhadi S, Irandoust M, Khazaei-Poul Y, Chaleshtari MGhasemi, Fathabad MEdalati, Baghaei M, Haghnavaz N, et al. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. Int J Biol Macromol. 2020.
Hashemi V, Ahmadi A, Malakotikhah F, Chaleshtari MGhasemi, Moornani MBaghi, Masjedi A, Sojoodi M, Atyabi F, Nikkhoo A, Rostami N, et al. Silencing of p68 and STAT3 synergistically diminishes cancer progression. Life Sci. 2020:117499.
Khosravi N, Pishavar E, Baradaran B, Oroojalian F, Mokhtarzadeh A. Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics. J Control Release. 2022.
Sayadmanesh A, Yekehfallah V, Valizadeh A, Abedelahi A, Shafaei H, Shanehbandi D, Basiri M, Baradaran B. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer. Int Immunopharmacol. 2023;125(Pt A):111093.
Pourradi NMohammad A, Babaei H, Hamishehkar H, Baradaran B, Shokouhi-Gogani B, Shanehbandi D, Ghorbani M, Azarmi Y. Targeted delivery of doxorubicin by Thermo/pH-responsive magnetic nanoparticles in a rat model of breast cancer. Toxicol Appl Pharmacol. 2022:116036.